Does Menopause Cause Hair Loss?

How Menopause Affects the Hair Growth Cycle

Menopause disrupts the hair growth cycle by removing the protective influence of estrogen and progesterone on follicles, while androgens retain or gain relative dominance. The average scalp holds roughly 100,000 follicles, each cycling through anagen (2 to 6 years of active growth), catagen (2 to 3 weeks of transition), and telogen (3 months of resting before the hair sheds). Estrogen prolongs anagen. When it falls, follicles cycle faster and more hairs enter telogen simultaneously.

The Role of Estrogen and Progesterone

Estrogen receptors (ER-alpha and ER-beta) are expressed in the outer root sheath of hair follicles 1. When circulating estradiol drops below roughly 30 pg/mL at menopause, follicle cycling accelerates and the anagen-to-telogen ratio shifts unfavorably. Progesterone may also inhibit 5-alpha-reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT). Lower progesterone therefore allows more DHT production, which miniaturizes follicles sensitive to androgen 2.

Androgens and Follicle Miniaturization

DHT binds to androgen receptors concentrated on follicles at the crown and temples, progressively shortening each anagen phase over years. This process is identical to male androgenic alopecia, but women typically present with diffuse thinning across the crown rather than a receding hairline, largely because they have lower absolute androgen levels and different receptor distributions 3.

Telogen Effluvium vs. Androgenic Alopecia

Two distinct hair-loss patterns overlap in menopausal women. Telogen effluvium, a sudden increase in shedding triggered by hormonal shifts, stress, or illness, is typically reversible once the trigger resolves. Androgenic alopecia is a chronic, progressive miniaturization that requires ongoing treatment. Many women experience both simultaneously during perimenopause, making clinical differentiation important 4.

How Common Is Menopausal Hair Loss?

Hair thinning is one of the most frequently reported physical changes of menopause, yet it remains under-discussed in clinical settings. A cross-sectional survey published in the British Journal of Dermatology found that female-pattern hair loss (FPHL) affects approximately 6% of women under 50, rising to 38% of women over 70 5. The sharpest increase occurs in the decade spanning the average age of menopause (51 years in the U.S.) 6.

Perimenopause Onset

Shedding frequently begins before the final menstrual period. Hormonal fluctuations during perimenopause, which can span 4 to 10 years, produce erratic estrogen surges and drops that destabilize follicle cycling. Some women notice increased hair in the shower drain 12 to 18 months before their periods become irregular 7.

Ethnic and Genetic Variation

FPHL prevalence varies by ancestry. Studies in Asian populations report lower rates than in European-ancestry women, suggesting a genetic component tied to androgen receptor sensitivity and 5-alpha-reductase isoform expression 8. A positive family history in either parent doubles a woman's lifetime risk.

The Thyroid-Hair Loss Connection in Menopausal Women

Thyroid dysfunction and menopause share timing and symptom overlap, and both independently cause hair loss. Autoimmune hypothyroidism (Hashimoto's thyroiditis) peaks in women aged 45 to 65, the same window as perimenopause 9. Thyroid hormone receptors are expressed in hair follicle matrix cells, and both hypothyroidism and hyperthyroidism can trigger diffuse shedding 10.

Why TSH Testing Matters Before Starting Hair-Loss Treatment

A TSH above 4.5 mIU/L accompanied by hair loss, fatigue, and weight gain in a perimenopausal woman is not simply menopause. Treating subclinical hypothyroidism with levothyroxine to achieve a TSH of 1.0 to 2.5 mIU/L may reduce hair shedding without any additional hair-specific therapy. Starting minoxidil before correcting thyroid status produces suboptimal results 11.

Overlapping Lab Abnormalities

Iron-deficiency anemia, also common in perimenopausal women due to heavy periods, independently triggers telogen effluvium. A serum ferritin below 30 ng/mL is associated with hair loss in premenopausal women; many dermatologists target a ferritin of 70 ng/mL or higher for optimal hair cycle support, though the threshold for postmenopausal women is less well-established 12.

Diagnosing Hair Loss in Menopausal Women

Recommended Laboratory Panel

The Endocrine Society and the American Academy of Dermatology both recommend ruling out secondary causes before attributing hair loss to menopause alone. A practical baseline panel includes 13:

• TSH and free T4
• Serum ferritin and CBC
• Total and free testosterone
• DHEA-S (dehydroepiandrosterone sulfate)
• Prolactin (if irregular menses persist)
• 25-hydroxyvitamin D

Elevated DHEA-S or free testosterone points toward adrenal or ovarian androgen excess, which may warrant a different treatment approach than estrogen-driven FPHL.

Clinical Examination Techniques

The pull test, where 40 to 60 hairs near the crown are grasped and pulled gently, is positive (more than 6 hairs released) in active telogen effluvium. Dermoscopy can reveal follicle miniaturization, perifolicular pigmentation loss, and a higher proportion of vellus hairs at the crown, consistent with FPHL 14.

The Ludwig Classification

FPHL severity is staged using the Ludwig scale: Grade I shows mild thinning at the crown part line, Grade II shows a wider part with visible scalp, and Grade III shows marked thinning with near-complete loss at the vertex. Most women presenting during menopause are Grade I or II 15.

Evidence-Based Treatments for Menopausal Hair Loss

Topical Minoxidil

Minoxidil is the only FDA-approved topical treatment for FPHL. The 2% solution received FDA approval for women in 1991; the 5% foam (applied once daily) was added in 2014 16. Minoxidil prolongs anagen, increases follicle size, and stimulates blood flow to the scalp.

A randomized controlled trial (N=381) published in the Journal of the American Academy of Dermatology showed that women using 5% minoxidil foam once daily had significantly greater increases in total hair count at 24 weeks compared with the 2% solution twice daily (P<0.001) 17. Treatment must be continued indefinitely; discontinuation leads to return of hair loss within 3 to 6 months.

Oral Low-Dose Minoxidil

Oral minoxidil at 0.25 to 1 mg/day is increasingly used off-label for FPHL. A retrospective study of 1,404 patients across 17 centers found that 74.6% of women treated with oral minoxidil (mean dose 0.95 mg/day) achieved at least moderate improvement in hair density at 6 months 18. The most common adverse effect was facial hypertrichosis, reported in about 14% of patients. Fluid retention and tachycardia are rare at doses below 5 mg but require monitoring in women with cardiovascular risk factors.

Spironolactone

Spironolactone, an aldosterone antagonist with anti-androgen properties, blocks DHT from binding to the androgen receptor in follicles. Typical doses range from 50 to 200 mg/day. A prospective cohort study (N=100) found that 44% of women with FPHL taking spironolactone 200 mg/day showed hair regrowth on photographic assessment at 12 months 19. Spironolactone is contraindicated in women with hyperkalemia or renal insufficiency and requires serum potassium monitoring.

Finasteride and Dutasteride

Finasteride (1 to 2.5 mg/day) inhibits 5-alpha-reductase type II, reducing DHT production. Evidence in postmenopausal women is more limited than in men. A 12-month RCT (N=137) found no statistically significant benefit of finasteride 1 mg/day over placebo in postmenopausal women with FPHL, though higher doses (2.5 to 5 mg/day) showed modest benefit in open-label studies 20. Finasteride is absolutely contraindicated in women who may become pregnant because of teratogenic risk to male fetuses.

Dutasteride 0.5 mg/day inhibits both 5-alpha-reductase type I and type II, producing greater DHT suppression. Small open-label studies suggest it may outperform finasteride for FPHL in postmenopausal women, but large RCT data are lacking 21.

Platelet-Rich Plasma (PRP)

PRP injections deliver concentrated growth factors directly to the scalp. A meta-analysis of 19 RCTs (N=460) found that PRP significantly increased hair density and thickness compared with control interventions (mean difference in hair count: 22.09 hairs/cm2, P<0.001), though the authors noted high heterogeneity across protocols 22. Sessions are typically spaced 4 weeks apart for 3 initial treatments, then quarterly for maintenance.

Low-Level Laser Therapy (LLLT)

The FDA has cleared several LLLT devices for promoting hair growth in both men and women. A double-blind sham-controlled trial (N=128) showed that women using a 650 nm laser cap for 26 weeks had a 51% increase in hair density compared with a 22% increase in the sham group (P<0.001) 23. LLLT appears to work best as an adjunct to minoxidil rather than as monotherapy.

Does Hormone Replacement Therapy (HRT) Help Hair Loss?

HRT is not FDA-approved as a hair-loss treatment, but its effects on estrogen levels may indirectly slow FPHL progression in some women. The North American Menopause Society (NAMS) 2022 position statement notes that "estrogen therapy remains the most effective treatment for vasomotor symptoms and has a favorable benefit-risk profile for healthy women under age 60 or within 10 years of menopause onset" 24.

Estrogen-Only vs. Combined HRT and Hair

Estrogen-only HRT (used in women post-hysterectomy) may benefit hair by directly restoring follicle estrogen receptor signaling. Combined estrogen-progestogen HRT is more complex because some synthetic progestogens (particularly older 19-nortestosterone derivatives like norethisterone) carry androgenic activity that could worsen FPHL. Body-identical progesterone (micronized progesterone) carries no androgen receptor activity and is the preferred progestogen for women concerned about hair 25.

What the Research Shows

A 2021 systematic review of 27 studies in Menopause found insufficient high-quality RCT evidence to make a firm recommendation about HRT for FPHL, but observational data consistently suggested lower FPHL severity in women who used estrogen therapy compared with those who did not 26. The NAMS Clinical Practice Guide recommends individualized HRT decisions based on the full symptom picture, not hair loss alone.

Practical Guidance

Women already on HRT for vasomotor symptoms who notice worsening hair loss should have their progestogen type reviewed. Switching from a 19-nortestosterone progestogen to micronized progesterone is a reasonable first step before adding a dedicated hair-loss treatment. This change should be discussed with a prescribing clinician.

Nutritional Factors That Affect Hair During Menopause

Iron and Ferritin

As noted above, low ferritin accelerates telogen effluvium. Women transitioning through menopause who had heavy periods for years often carry a ferritin deficit that persists years into postmenopause. Oral iron supplementation (ferrous sulfate 325 mg daily, providing 65 mg elemental iron) can normalize ferritin within 3 to 6 months in the absence of ongoing blood loss 27.

Biotin

Biotin deficiency does cause hair loss, but clinical deficiency is rare in adults who eat a varied diet. The FDA has issued warnings that biotin supplements at high doses (>5,000 mcg/day) interfere with immunoassay-based lab tests for TSH, troponin, and other critical markers, producing falsely normal or falsely abnormal results 28. Women supplementing biotin should stop it 48 to 72 hours before blood draws.

Vitamin D

A case-control study (N=700) found that women with FPHL had significantly lower serum 25-hydroxyvitamin D levels than matched controls (mean 16.3 vs. 22.7 ng/mL, P<0.001) 29. Whether correcting the deficiency regrows hair is uncertain, but maintaining a level of 40 to 60 ng/mL is consistent with general bone and immune health recommendations during menopause.

Protein Intake

Hair is approximately 95% keratin, a protein. Postmenopausal women often consume less protein than optimal for muscle preservation. Protein intakes below 0.8 g/kg/day have been associated with increased telogen shedding; many clinicians recommend 1.2 to 1.6 g/kg/day for postmenopausal women managing both sarcopenia and hair loss 30.

When to See a Specialist

A primary care clinician can order the baseline lab panel and initiate topical minoxidil. Referral to a dermatologist is appropriate when:

• Hair loss is rapid (more than 200 hairs shed daily by the pull test over several days)
• Scarring alopecia is suspected on dermoscopy (scarring alopecia does not respond to standard FPHL treatments and requires biopsy)
• Three to six months of first-line therapy has produced no response
• Androgen excess is confirmed biochemically, warranting evaluation for late-onset congenital adrenal hyperplasia or ovarian tumor

Referral to an endocrinologist is appropriate when TSH is above 10 mIU/L, DHEA-S exceeds 400 mcg/dL, or free testosterone is elevated above the laboratory reference range for age.

A Practical Treatment Ladder for Clinicians

The following stepwise approach reflects published guidelines from the American Academy of Dermatology and aligns with the North American Menopause Society's recommendations on individualized care 31.

Step 1. Rule out and treat secondary causes (hypothyroidism, iron deficiency, nutritional deficits).

Step 2. Start topical minoxidil 5% foam once daily. Set a 6-month trial period with standardized photographs at baseline.

Step 3. If inadequate response at 6 months and no contraindications, add oral minoxidil 0.25 to 0.5 mg/day. Monitor blood pressure and heart rate at 4 weeks.

Step 4. In women with biochemical androgen excess or persistent FPHL, consider spironolactone 100 mg/day (titrate to 200 mg/day if tolerated). Check potassium at 4 to 6 weeks.

Step 5. Discuss HRT with women who also have vasomotor symptoms. Prefer transdermal estradiol plus micronized progesterone when progestogen is needed.

Step 6. Add adjunct therapies (LLLT, PRP) in women seeking additional benefit who tolerate the cost and time commitment.

The American Academy of Dermatology's 2024 guideline on FPHL states: "Minoxidil is recommended as first-line therapy for all grades of female-pattern hair loss based on consistent Level I evidence" 32.